(Q80557811)
Statements
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies (English)
Bret Wacker
Tina Nagrani
Jacqueline Weinberg
Karsten Witt
Gary Clark